公开(公告)号：US10004636B2

公开(公告)日：2018-06-26

申请号：US15230275

申请日：2016-08-05

Applicant: Forsight Vision5, Inc.

Inventor： Yair Alster ,  Eugene de Juan, Jr. ,  Cary J. Reich ,  Stephen Boyd ,  David Sierra ,  Jose D. Alejandro ,  K. Angela Macfarlane ,  Douglas Sutton

IPC: A61F9/00 ,  A61M35/00 ,  A61K9/00 ,  A61K31/19 ,  A61K31/407 ,  A61K31/4178 ,  A61K31/5377 ,  A61K31/5415 ,  A61K31/43 ,  A61K31/55 ,  A61K31/557 ,  A61K31/5575 ,  A61K31/56 ,  A61K31/568 ,  A61K31/573 ,  A61K31/58 ,  A61K31/7036 ,  A61K38/00 ,  A61M31/00 ,  A61K31/335

CPC classification number: A61F9/0026 ,  A61F9/0017 ,  A61K9/0051 ,  A61K31/19 ,  A61K31/335 ,  A61K31/407 ,  A61K31/4178 ,  A61K31/43 ,  A61K31/5377 ,  A61K31/5415 ,  A61K31/55 ,  A61K31/557 ,  A61K31/5575 ,  A61K31/56 ,  A61K31/568 ,  A61K31/573 ,  A61K31/58 ,  A61K31/7036 ,  A61K38/00 ,  A61M31/002

Abstract: A therapeutic system comprises an ocular insert placed on a region outside an optical zone of an eye. The ocular insert comprises two structures: a first skeletal structure and a second cushioning structure. The first structure functions as a skeletal frame which maintains positioning of the implant along the anterior portion of the eye and provides support to the second, cushioning structure. This first structure maintains the attachment of the therapeutic system to the anterior portion of the eye for at least thirty days. In some embodiments the first structure remains a constant size and shape, e.g. a ring shape, a ring with haptics, or a curvilinear ring that is confined to and restrainingly engages the inferior and superior conjunctival fornices so as to retain the implant within the tear fluid and/or against the tissues of the eye.

公开(公告)号：US20180161312A1

公开(公告)日：2018-06-14

申请号：US15892846

申请日：2018-02-09

Applicant: Janssen Pharmaceutica NV

Inventor： Ishtiyaque Ahmad ,  Rajagopal Bakthavatchalam ,  Sivaramakrishna Battula ,  Henricus Jacobus Maria Gijsen ,  Saravanan Vadivelu ,  Mark Wall ,  Christopher Flores

IPC: A61K31/4178 ,  A61K31/506 ,  A61K31/497 ,  A61K31/444 ,  C07D405/14 ,  A61K31/4196 ,  C07D405/04 ,  A61K31/4439

CPC classification number: A61K31/4178 ,  A61K31/4196 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/497 ,  A61K31/506 ,  C07D405/04 ,  C07D405/14

Abstract: Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula (I) as follows: wherein R1, R2, R3, and G are defined herein.

公开(公告)号：US09987254B2

公开(公告)日：2018-06-05

申请号：US14225704

申请日：2014-03-26

Applicant: Eurocanarias Oftalmológica, S.L.

Inventor： Jose Vincent Rodriguez Hernandez ,  Humberto Carreras Diaz

IPC: A61K31/196 ,  A61K31/4178 ,  A61K9/00

CPC classification number: A61K31/4178 ,  A61K9/0048 ,  A61K31/196 ,  A61K2300/00

Abstract: Ophthalmic composition for the correction of presbyopia. Composition consisting of 2% Pilocarpine, characterized by being diluted to 1% with sterile Balanced Salt Solution (BSS), obtaining 1% pilocarpine (2.5 ml)+bromfenac, 1.8 mgrs of bromfenac (2.5 ml)+sterile Balanced Salt Solution (BSS) (2.5 ml), finally obtaining eye drops of 7.5 ml. It is also possible to obtain a 1.5% and 2% pilocarpine.

公开(公告)号：US09974774B2

公开(公告)日：2018-05-22

申请号：US14907729

申请日：2014-07-25

Applicant: UPDATE PHARMA INC.

Inventor： William J. Garner ,  Amie Franklin ,  John Rothman

IPC: A61K31/4178 ,  A61K45/06 ,  A61K31/4168 ,  A61K31/473 ,  A61K47/48

CPC classification number: A61K31/4178 ,  A61K31/4168 ,  A61K31/473 ,  A61K45/06 ,  A61K47/50 ,  A61K47/54

Abstract: The present invention describes methods and compositions for improving the therapeutic efficacy of therapeutic agents previously limited by suboptimal therapeutic performance by either improving efficacy as monotherapy or reducing side effects. Such methods and compositions are particularly applicable to bisantrene or derivatives, analogs, or prodrugs thereof.

公开(公告)号：US20180127386A1

公开(公告)日：2018-05-10

申请号：US15789869

申请日：2017-10-20

Applicant: FORMA Therapeutics, Inc. ,  H. Lee Moffitt Cancer Center and Research Institute, Inc.

Inventor： Jennifer Lee ,  Pearlie Burnette ,  Srikumar Chellappan ,  Nicholas Barczak ,  Jaime A. Escobedo ,  Chiara Conti ,  Bingsong Han ,  David R. Lancia, JR. ,  Cuixian Liu ,  Matthew W. Martin ,  Pui Yee Ng ,  Aleksandra Rudnitskaya ,  Jennifer R. Thomason ,  Xiaozhang Zheng

IPC: C07D263/58 ,  A61P35/00 ,  A61K31/423 ,  C07D413/12 ,  A61K31/4439 ,  A61K31/506 ,  C07D277/82 ,  A61K31/428 ,  C07D235/30 ,  A61K31/4184 ,  C07C53/06 ,  C07D209/40 ,  A61K31/404 ,  C07D473/00 ,  A61K31/52 ,  C07D487/04 ,  A61K31/4985 ,  C07D498/04 ,  A61K31/437 ,  C07D491/056 ,  A61K31/4188 ,  A61K31/5383 ,  C07D401/04 ,  A61K31/4709 ,  C07D405/04 ,  A61K31/4178 ,  C07D403/04 ,  A61K31/5377 ,  C07D209/54 ,  A61K31/403 ,  C07D413/06 ,  A61K31/422 ,  C07D401/14 ,  C07D401/06 ,  C07D413/14 ,  A61K31/4245 ,  C07D417/06 ,  A61K31/427 ,  C07D403/06 ,  A61K31/4192 ,  C07D221/20 ,  A61K31/438 ,  C07D491/107 ,  A61K31/435 ,  A61K45/06

CPC classification number: C07D263/58 ,  A61K31/403 ,  A61K31/404 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/4188 ,  A61K31/4192 ,  A61K31/422 ,  A61K31/423 ,  A61K31/4245 ,  A61K31/427 ,  A61K31/428 ,  A61K31/435 ,  A61K31/437 ,  A61K31/438 ,  A61K31/4439 ,  A61K31/4709 ,  A61K31/4985 ,  A61K31/506 ,  A61K31/52 ,  A61K31/5377 ,  A61K31/5383 ,  A61K45/06 ,  A61P35/00 ,  C07C53/06 ,  C07D209/40 ,  C07D209/54 ,  C07D221/20 ,  C07D235/30 ,  C07D277/82 ,  C07D401/04 ,  C07D401/06 ,  C07D401/14 ,  C07D403/04 ,  C07D403/06 ,  C07D405/04 ,  C07D413/06 ,  C07D413/12 ,  C07D413/14 ,  C07D417/06 ,  C07D473/00 ,  C07D487/04 ,  C07D491/056 ,  C07D491/107 ,  C07D498/04

Abstract: The present invention provides methods and uses of inhibitors of histone deacetylase 11 (HDAC11) in the treatment of diseases and/or disorders, such as, for example, cell proliferative diseases.

公开(公告)号：US20180117038A1

公开(公告)日：2018-05-03

申请号：US15827539

申请日：2017-11-30

Applicant: Buck Institute for Research on Aging ,  Mayo Foundation for Medical Education and Research ,  Unity Biotechnology, Inc.

Inventor： Remi-Martin Laberge ,  Judith Campisi ,  Marco Demaria ,  Nathaniel David ,  Alain Philippe Vasserot ,  James L. Kirkland ,  Tamar Tchkonia ,  Yi Zhu

IPC: A61K31/496 ,  A61K31/728 ,  A61K31/4178

CPC classification number: A61K31/496 ,  A61K9/0048 ,  A61K9/0073 ,  A61K31/404 ,  A61K31/4178 ,  A61K31/428 ,  A61K31/4375 ,  A61K31/495 ,  A61K31/5377 ,  A61K31/728 ,  A61K45/06 ,  A61K47/36 ,  C12N5/0081 ,  C12N2501/999 ,  C12N2503/02

Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.

公开(公告)号：US09938234B2

公开(公告)日：2018-04-10

申请号：US14874008

申请日：2015-10-02

Applicant: Salk Institute for Biological Studies ,  Mitobridge, Inc.

Inventor： Ronald M. Evans ,  Michael Downes ,  Thomas J. Baiga ,  Joseph P. Noel ,  Emi Kanakubo Embler ,  Weiwei Fan ,  John F. W. Keana ,  Mark G. Bock ,  Arthur F. Kluge ,  Mike A. Patane

IPC: C07C233/87 ,  C07D231/12 ,  C07D233/24 ,  C07D405/12 ,  C07D213/56 ,  C07D307/54 ,  C07C255/57 ,  C07C317/44 ,  C07C233/73 ,  C07C235/42 ,  C07C235/48 ,  C07C235/84 ,  C07C237/22 ,  C07D309/06 ,  C07D405/04 ,  C07D405/10 ,  C07D407/12 ,  A61K31/381 ,  A61K31/5377 ,  A61K31/44 ,  A61K31/4025 ,  A61K31/422 ,  A61K31/341 ,  A61K31/427 ,  A61K31/164 ,  A61K31/4178 ,  C07D333/24 ,  C07C237/32 ,  C07D413/04 ,  C07D413/10 ,  C07D413/12 ,  C07D417/04 ,  C07D417/10 ,  C07D417/12 ,  C07D207/04 ,  C07D271/12 ,  C07D209/34 ,  C07D295/13 ,  C07D305/06 ,  C07D307/83 ,  C07C237/48 ,  C07C259/06

CPC classification number: C07C233/87 ,  A61K31/164 ,  A61K31/341 ,  A61K31/381 ,  A61K31/4025 ,  A61K31/4178 ,  A61K31/422 ,  A61K31/427 ,  A61K31/44 ,  A61K31/5377 ,  C07C233/73 ,  C07C235/42 ,  C07C235/48 ,  C07C235/84 ,  C07C237/22 ,  C07C237/32 ,  C07C237/48 ,  C07C255/57 ,  C07C259/06 ,  C07C317/44 ,  C07C2601/02 ,  C07D207/04 ,  C07D209/34 ,  C07D213/56 ,  C07D231/12 ,  C07D271/12 ,  C07D295/13 ,  C07D305/06 ,  C07D307/54 ,  C07D307/83 ,  C07D309/06 ,  C07D333/24 ,  C07D405/04 ,  C07D405/10 ,  C07D405/12 ,  C07D407/12 ,  C07D413/04 ,  C07D413/10 ,  C07D413/12 ,  C07D417/04 ,  C07D417/10 ,  C07D417/12

Abstract: Provided herein are compounds and compositions useful in increasing PPARδ activity. The compounds and compositions provided herein are useful for the treatment of PPARδ related diseases (e.g., muscular diseases, vascular disease, demyelinating disease, and metabolic diseases).

公开(公告)号：US09918989B2

公开(公告)日：2018-03-20

申请号：US14904673

申请日：2014-07-11

Applicant: The Regents of the University of California

Inventor： Shirley Luckhart ,  Cecilia Giulivi

IPC: A61K39/00 ,  A61K31/5377 ,  A61K45/06 ,  A61K31/4162 ,  G01N33/569 ,  A61K31/416 ,  A61K31/4439 ,  A61K49/00 ,  C12Q1/48 ,  G01N33/50 ,  G01N33/573 ,  A61K31/4035 ,  A61K31/404 ,  A61K31/407 ,  A61K31/4168 ,  A61K31/4178 ,  A61K31/473 ,  A61K31/52 ,  A61K31/541

CPC classification number: A61K31/5377 ,  A61K31/4035 ,  A61K31/404 ,  A61K31/407 ,  A61K31/416 ,  A61K31/4162 ,  A61K31/4168 ,  A61K31/4178 ,  A61K31/4439 ,  A61K31/473 ,  A61K31/52 ,  A61K31/541 ,  A61K45/06 ,  A61K49/0008 ,  C12Q1/485 ,  G01N33/5008 ,  G01N33/5014 ,  G01N33/56905 ,  G01N33/573 ,  G01N2333/445 ,  G01N2333/912 ,  G01N2440/14 ,  G01N2500/04 ,  G01N2500/10 ,  G01N2500/20 ,  Y02A50/409 ,  Y02A50/411 ,  Y02A50/414

Abstract: The present disclosure provides methods for treating or preventing malaria by administration of a protein kinase inhibitor and optionally one or both of a further protein kinase inhibitor and an antimalarial drug to a mammalian subject infected with or at risk of exposure to Plasmodium sp. In some aspects, the therapeutic and prophylactic regimens of the present disclosure are effective in reducing parasite development in mosquitoes feeding on recipients of the regimens. Additionally, the present disclosure provides methods for screening candidate antimalarial agents.

公开(公告)号：US20180072701A1

公开(公告)日：2018-03-15

申请号：US15560365

申请日：2016-03-24

Applicant: Toray Industries, Inc.

Inventor： Yuji Osada ,  Naoki Izumimoto ,  Yasuhiro Morita ,  Shuji Udagawa ,  Katsuhiko Iseki ,  Tomoya Miyoshi ,  Shunsuke Iwano

IPC: C07D401/06 ,  C07D403/06

CPC classification number: C07D401/06 ,  A61K31/4178 ,  A61K31/454 ,  C07D403/06

Abstract: A cyclic amine derivative represented by a general formula (I) or a pharmacologically acceptable salt thereof: wherein n represents 1 or 3, R1 represents an alkyl group having 1 to 6 carbon atoms unsubstituted, substituted with a halogen atom or substituted with an alkyloxy group having 1 to 4 carbon atoms and R2 represents a hydrogen atom or a halogen atom.

公开(公告)号：US20180071272A1

公开(公告)日：2018-03-15

申请号：US15520317

申请日：2015-10-19

Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA

Inventor： JOHN B. HOGENESCH ,  GARRET A. FITZGERALD

IPC: A61K31/455 ,  A61K31/41 ,  A61K31/4178 ,  A61K31/138 ,  A61K31/5377 ,  A61K31/549 ,  A61K38/05 ,  A61K31/192 ,  A61K31/405

CPC classification number: A61K31/455 ,  A61K31/138 ,  A61K31/192 ,  A61K31/195 ,  A61K31/366 ,  A61K31/405 ,  A61K31/41 ,  A61K31/4178 ,  A61K31/4418 ,  A61K31/5377 ,  A61K31/549 ,  A61K31/7008 ,  A61K38/05

Abstract: The invention includes a formulation of a therapeutic compound, wherein release of the therapeutic compound from the formulation coincides with peak or trough expression of at least one target gene of the therapeutic compound. The invention also includes a method of developing such formulations and a method of treating a disorder in a subject using such formulations.